Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.15 +1.38 (+2.57%)
Official Closing Price Updated: 4:15 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
News headline image
2 Soaring Stocks to Buy and Hold Through 2023 and Beyond ↗
Investors are bidding up shares of these companies, and there are good reasons for doing so. 
Via The Motley Fool
News headline image
10 Best Stocks to Buy in March 2023 ↗
These diversified growth stocks could add rocket fuel to your long-term investment portfolio. 
Via The Motley Fool
News headline image
Expert Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Here's How Much You Can Make From Investing Your Tax Return Every Year ↗
Doing this can strengthen your retirement plan. 
Via The Motley Fool
News headline image
Looking Into CRISPR Therapeutics's Return On Invested Capital ↗
 
Via Benzinga
News headline image
Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
News headline image
Beat the Dow Jones With CRISPR Therapeutics Stock ↗
If approved, CRISPR's first product may deliver blockbuster sales. 
Via The Motley Fool
News headline image
Top CRISPR Stocks ↗
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
News headline image
Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗
The gene-editing business has loads of potential, but is it enough to make you rich? 
Via The Motley Fool
News headline image
2 Bruised Growth Stocks to Buy While They're Cheap ↗
Both are on the verge of fast growth, and they haven't had any major setbacks yet. 
Via The Motley Fool
News headline image
SMID Cap Life Science Update: Are You An Investor Or Trader? ↗
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
News headline image
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer ↗
These two companies are on track to flourish through the end of the decade. 
Via The Motley Fool
News headline image
These 2 Biotech Stocks Could Soar in the Next Bull Market ↗
They're both at the cutting edge of gene-editing technology. 
Via The Motley Fool
News headline image
3 Prime Healthcare Takeover Targets ↗
These three companies are attractive targets for their potential. 
Via The Motley Fool
News headline image
The Best Stocks To Invest $5,000 in Right Now ↗
The time is right for each of these great stocks. 
Via The Motley Fool
News headline image
Ready to Buy the Dip? Consider This Gene Editing Stock ↗
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back. 
Via The Motley Fool
News headline image
These Cheap Growth Stocks Could Supercharge Your Portfolio ↗
All of these players are cheap today considering their growth potential. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Stock a Buy Right Now? ↗
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains? 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Patience will pay off with these two stocks. 
Via The Motley Fool
News headline image
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals? ↗
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals. 
Via The Motley Fool
News headline image
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen. ↗
CRISPR shares are ripe for a rebound after dropping 46% last year. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock That Has a Lot to Prove in 2023 ↗
This biotech looks like a high-risk, high-reward play. 
Via The Motley Fool
News headline image
3 Top Stocks to Buy If There Is a Market Pullback ↗
All three of these stocks performed well as the market fell in 2022. 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
News headline image
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
News headline image
3 No-Brainer Growth Stocks to Buy in 2023 ↗
These stocks all fell by double digits last year. 
Via The Motley Fool
News headline image
Why Editas Medicine's Shares Jumped This Week ↗
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
News headline image
Is Editas Medicine Stock a Buy Now? ↗
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
News headline image
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
News headline image
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now? ↗
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case? 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.